These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 19895367)
1. Design and in vitro evaluation of novel sustained- release matrix tablets for lornoxicam based on the combination of hydrophilic matrix formers and basic pH-modifiers. Hamza Yel-S; Aburahma MH Pharm Dev Technol; 2010; 15(2):139-53. PubMed ID: 19895367 [TBL] [Abstract][Full Text] [Related]
3. Innovation of novel sustained release compression-coated tablets for lornoxicam: formulation and in vitro investigations. Hamza Yel-S; Aburahma MH Drug Dev Ind Pharm; 2010 Mar; 36(3):337-49. PubMed ID: 19722915 [TBL] [Abstract][Full Text] [Related]
4. Design and in vitro evaluation of novel sustained-release double-layer tablets of lornoxicam: utility of cyclodextrin and xanthan gum combination. Hamza Yel-S; Aburahma MH AAPS PharmSciTech; 2009; 10(4):1357-67. PubMed ID: 19921543 [TBL] [Abstract][Full Text] [Related]
5. Sustained-release matrix tablets of metformin hydrochloride in combination with triacetyl-beta-cyclodextrin. Corti G; Cirri M; Maestrelli F; Mennini N; Mura P Eur J Pharm Biopharm; 2008 Feb; 68(2):303-9. PubMed ID: 17616379 [TBL] [Abstract][Full Text] [Related]
6. Sustained delivery of captopril from floating matrix tablets. Jiménez-Martínez I; Quirino-Barreda T; Villafuerte-Robles L Int J Pharm; 2008 Oct; 362(1-2):37-43. PubMed ID: 18588962 [TBL] [Abstract][Full Text] [Related]
7. pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations. Riis T; Bauer-Brandl A; Wagner T; Kranz H Eur J Pharm Biopharm; 2007 Jan; 65(1):78-84. PubMed ID: 16919924 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC. Shoaib MH; Tazeen J; Merchant HA; Yousuf RI Pak J Pharm Sci; 2006 Apr; 19(2):119-24. PubMed ID: 16751122 [TBL] [Abstract][Full Text] [Related]
9. Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug. Kranz H; Guthmann C; Wagner T; Lipp R; Reinhard J Eur J Pharm Sci; 2005 Sep; 26(1):47-53. PubMed ID: 15953712 [TBL] [Abstract][Full Text] [Related]
10. Comparative study on the in vitro performance of blister molded and conventional lornoxicam immediate release liquitablets: accelerated stability study and anti-inflammatory and ulcerogenic effects. El-Setouhy DA; Gamiel AA; Badawi AA; Osman AS; Labib DA Pharm Dev Technol; 2017 Mar; 22(2):256-265. PubMed ID: 27494155 [TBL] [Abstract][Full Text] [Related]
11. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen. Cao QR; Choi YW; Cui JH; Lee BJ J Control Release; 2005 Nov; 108(2-3):351-61. PubMed ID: 16154656 [TBL] [Abstract][Full Text] [Related]
12. High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation. Nabais T; Brouillet F; Kyriacos S; Mroueh M; Amores da Silva P; Bataille B; Chebli C; Cartilier L Eur J Pharm Biopharm; 2007 Mar; 65(3):371-8. PubMed ID: 17275270 [TBL] [Abstract][Full Text] [Related]
13. Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: in vitro and in vivo evaluation in healthy volunteers. Xu X; Sun M; Zhi F; Hu Y Int J Pharm; 2006 Mar; 310(1-2):139-45. PubMed ID: 16413710 [TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of pH-independent sustained release tablet containing solid dispersion granules of a poorly water-soluble drug. Tran HT; Park JB; Hong KH; Choi HG; Han HK; Lee J; Oh KT; Lee BJ Int J Pharm; 2011 Aug; 415(1-2):83-8. PubMed ID: 21641985 [TBL] [Abstract][Full Text] [Related]
15. Design of pH-independent extended release matrix tablets of minocycline hydrochloride for the treatment of dementia. Cha KH; Park J; Cho W; Gu DG; Jeong K; Hwang SJ Arch Pharm Res; 2009 Nov; 32(11):1593-8. PubMed ID: 20091273 [TBL] [Abstract][Full Text] [Related]
16. Preparation and evaluation of novel metronidazole sustained release and floating matrix tablets. Asnaashari S; Khoei NS; Zarrintan MH; Adibkia K; Javadzadeh Y Pharm Dev Technol; 2011 Aug; 16(4):400-7. PubMed ID: 20429828 [TBL] [Abstract][Full Text] [Related]
17. Influence of soluble and insoluble cyclodextrin polymers on drug release from hydroxypropyl methylcellulose tablets. Zugasti ME; Zornoza A; Goñi Mdel M; Isasi JR; Vélaz I; Martín C; Sánchez M; Martínez-Ohárriz MC Drug Dev Ind Pharm; 2009 Oct; 35(10):1264-70. PubMed ID: 19555243 [TBL] [Abstract][Full Text] [Related]
18. Dissolution enhancement and formulation of rapid-release lornoxicam mini-tablets. Tawfeek HM; Saleem IY; Roberts M J Pharm Sci; 2014 Aug; 103(8):2470-83. PubMed ID: 24995853 [TBL] [Abstract][Full Text] [Related]
19. The influence of protonation ratio on properties of carboxymethyl starch excipient at various substitution degrees: Structural insights and drug release kinetics. Assaad E; Mateescu MA Int J Pharm; 2010 Jul; 394(1-2):75-84. PubMed ID: 20435114 [TBL] [Abstract][Full Text] [Related]
20. Carboxymethyl high amylose starch as excipient for controlled drug release: mechanistic study and the influence of degree of substitution. Lemieux M; Gosselin P; Mateescu MA Int J Pharm; 2009 Dec; 382(1-2):172-82. PubMed ID: 19716866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]